Long intergenic non-protein coding RNA 320 (LINC00320)

Long intergenic non-protein coding RNA 320 (LINC00320) is a long non-coding RNA molecule specifically expressed in the human brain, predominantly in the white matter, and not found in non-human primates[1][2][3]. In cancer biology, especially in glioma, LINC00320 is notable for its tumor-suppressive functions; its expression levels are reduced in malignant glioma tissues and correlate inversely with patient prognosis[1][2]. Mechanistically, LINC00320 inhibits glioma cell proliferation by binding to β-catenin and disrupting the formation of the β-catenin/TCF4 complex, thereby restraining Wnt/β-catenin pathway activity[1][2]. Additionally, LINC00320 can bind to and modulate the nuclear localization and phosphorylation of nuclear factor κB subunit 1 (NFKB1), reducing the expression of the aquaporin 9 (AQP9) gene, leading to decreased glioma cell growth and angiogenesis[2]. Outside of oncology, its selective expression in human brain tissue and links to neural regulatory networks suggest additional roles in higher cognitive function[1]. LINC00320 may participate in immune regulation within the tumor microenvironment[1]. At present, there are no known drugs that directly target LINC00320, and it does not currently serve as a therapeutic target in the conventional sense (e.g., receptor, enzyme, transporter)[1][2][3][5]. Note: LINC00320 is classified as a long non-coding RNA and not as a receptor, enzyme, or other typical drug target molecule. Its principal importance is as a regulator of gene expression and as a tumor suppressor in glioma; it is under consideration as a prognostic biomarker, but not as a therapeutic target for small-molecule or antibody drugs at this time[1][2][3][5].

Other names

PRED14FLJ37539C21orf131NCRNA00320LINC00320C21ORF131